Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer

International Journal of Cancer

Volumn 131, Issue 6, 2012, Pages

  Shen, Jie ^a   Wang, Hao ^a   Wei, Jia ^a   Yu, Lixia ^a   Xie, Li ^a   Qian, Xiaoping ^a   Zou, Zhengyun ^a   Liu, Baorui ^a   Guan, Wenxian ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

cell free mRNA; chemosensitivity; gastric cancer; raltitrexed; TS

Indexed keywords

BIOLOGICAL MARKER; FOLIC ACID DERIVATIVE; MESSENGER RNA; QUINAZOLINE DERIVATIVE; RALTITREXED; THYMIDYLATE SYNTHASE;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER PATIENT; CANCER TISSUE; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TISSUE CULTURE; TISSUE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; RNA, MESSENGER; STOMACH NEOPLASMS; THIOPHENES; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84864144488     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27530     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE,. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-9.
3. Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ, Qian X, Chen H, Gimenez-Capitan A, Meng F, Moran T, Benlloch S, et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst 2011; 103: 1552-6.
4. Wesolowski R, Lee C, Kim R,. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol 2009; 10: 903-12.
5. Chin L, Andersen JN, Futreal PA,. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011; 17: 297-303.
6. Schilsky RL,. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010; 9: 363-6.
7. Hanauske AR, Eismann U, Oberschmidt O, Pospisil H, Hoffmann S, Hanauske-Abel H, Ma D, Chen V, Paoletti P, Niyikiza C,. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007; 25: 417-23.
8. Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC,. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011; 74: 132-8.
9. Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008; 98: 1398-402.
10. Rosell R, Moran T, Viteri S, Carcereny E, Gasco A, Quiroga V, Wei J, Camps C, Massuti B,. Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. Expert Opin Pharmacother 2010; 11: 1683-93.
11. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-91.
12. Van Cutsem E, Cunningham D, Maroun J, Cervantes A, Glimelius B,. Raltitrexed: current clinical status and future directions. Ann Oncol 2002; 13: 513-22.
13. Giovannetti E, Backus HH, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH, Poupon MF, Azzarello A, Pinedo HM, Peters GJ,. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007; 96: 769-75.
14. Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan PR, Avallone A, Budillon A,. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 2009; 8: 782-91.
15. Tzimagiorgis G, Michailidou EZ, Kritis A, Markopoulos AK, Kouidou S,. Recovering circulating extracellular or cell-free RNA from bodily fluids. Cancer Epidemiol 2011; 35: 580-9.
16. Nilsson RJ, Balaj L, Hulleman E, van Rijn S, Pegtel DM, Walraven M, Widmark A, Gerritsen WR, Verheul HM, Vandertop WP, Noske DP, Skog J, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011; 118: 3680-3.
17. Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O, Provencio M, Espana P, Bonilla F,. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res 2001; 7: 2821-5.
18. Silva JM, Rodriguez R, Garcia JM, Munoz C, Silva J, Dominguez G, Provencio M, Espana P, Bonilla F,. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 2002; 50: 530-4.
19. Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R, Esposito G, DelBianco P, Nitti D, De Rossi A,. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res 2008; 14: 7444-51.
20. Perhavec A, Cerkovnik P, Novakovic S, Zgajnar J,. The hTERT mRNA in plasma samples of early breast cancer patients, non-cancer patients and healthy individuals. Neoplasma 2008; 55: 549-54.
21. Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, Lorenzo Y, Diaz R, Espinosa P, de Sola JG, Cantos B, Bonilla F,. Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett 2008; 263: 312-20.
22. Wang L, Liu B, Wang T, Ding Y, Qian X, Zhao Y,. Detection of cell-free ERCC1 and thymidylate synthase (TS) mRNA in malignant effusions and its association with anticancer drug sensitivity. Anticancer Res 2008; 28: 1085-91.
23. Wang T, Qian X, Wang Z, Wang L, Yu L, Ding Y, Liu B,. Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions. Int J Cancer 2009; 125: 1921-5.
24. Garcia JM, Garcia V, Pena C, Dominguez G, Silva J, Diaz R, Espinosa P, Citores MJ, Collado M, Bonilla F,. Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA 2008; 14: 1424-32.
25. Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, Hurtado A, Alonso I, Rodriguez R, Provencio M, Bonilla F,. Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin Cancer Res 2006; 12: 2095-100.
26. Furukawa T, Kubota T, Hoffman RM,. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995; 1: 305-11.
27. Hayashi Y, Kuriyama H, Umezu H, Tanaka J, Yoshimasu T, Furukawa T, Tanaka H, Kagamu H, Gejyo F, Yoshizawa H,. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med 2009; 48: 203-8.
28. Hothorn T, Zeileis A,. Generalized maximally selected statistics. Biometrics 2008; 64: 1263-9.
29. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
30. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E, Ardalan B,. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 1999; 5: 34-40.
31. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P, Catalano G,. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999; 5: 1996-9.
32. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L,. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-12.
33. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14: 176-82.
34. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ, Johnston PG,. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000; 82: 560-7.
35. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV,. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-7.
36. Wong SC, Lo SF, Cheung MT, Ng KO, Tse CW, Lai BS, Lee KC, Lo YM,. Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res 2004; 10: 1613-7.
37. Fujita Y, Hiramatsu M, Kawai M, Nishimura H, Miyamoto A, Tanigawa N,. Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer. Oncol Rep 2009; 21: 499-505.
38. Miller BE, Miller FR, Heppner GH,. Assessing tumor drug sensitivity by a new in vitro assay which preserves tumor heterogeneity and subpopulation interactions. J Cell Physiol Suppl 1984; 3: 105-16.
39. Furukawa T, Kubota T, Tanino H, Oura S, Yuasa S, Murate H, Morita K, Kozakai K, Yano T, Hoffman RM,. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res 2000; 20: 3657-8.
40. Tanino H, Oura S, Hoffman RM, Kubota T, Furukawa T, Arimoto J, Yoshimasu T, Hirai I, Bessho T, Suzuma T, Sakurai T, Naito Y,. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res 2001; 21: 4083-6.
41. Yoshimasu T, Oura S, Hirai I, Tamaki T, Kokawa Y, Ota F, Nakamura R, Shimizu Y, Kawago M, Hirai Y, Naito K, Kiyoi M, et al. In vitro evaluation of dose-response curve for paclitaxel in breast cancer. Breast Cancer 2007; 14: 401-5.
42. Ariyoshi Y, Shimahara M, Tanigawa N,. Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol 2003; 39: 701-7.
43. Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T,. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 2007; 43: 749-56.
44. Samson DJ, Seidenfeld J, Ziegler K, Aronson N,. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004; 22: 3618-30.